These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1284 related items for PubMed ID: 19332033

  • 1. Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat.
    Allahtavakoli M, Moloudi R, Arababadi MK, Shamsizadeh A, Javanmardi K.
    Brain Res; 2009 May 19; 1271():121-7. PubMed ID: 19332033
    [Abstract] [Full Text] [Related]

  • 2. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke.
    Allahtavakoli M, Shabanzadeh AP, Sadr SS, Parviz M, Djahanguiri B.
    Clin Exp Pharmacol Physiol; 2006 Nov 19; 33(11):1052-8. PubMed ID: 17042914
    [Abstract] [Full Text] [Related]

  • 3. Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia.
    Yang Y, Li Q, Shuaib A.
    Exp Neurol; 2000 May 19; 163(1):39-45. PubMed ID: 10785442
    [Abstract] [Full Text] [Related]

  • 4. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
    Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J.
    Eur J Neurosci; 2005 Jul 19; 22(1):278-82. PubMed ID: 16029218
    [Abstract] [Full Text] [Related]

  • 5. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J.
    J Neurochem; 2006 Apr 19; 97(2):435-48. PubMed ID: 16539667
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
    Patzer A, Zhao Y, Stöck I, Gohlke P, Herdegen T, Culman J.
    Eur J Neurosci; 2008 Nov 19; 28(9):1786-94. PubMed ID: 18973594
    [Abstract] [Full Text] [Related]

  • 7. Neuroprotective effect of dapsone in an occlusive model of focal ischemia in rats.
    Ríos C, Nader-Kawachi J, Rodriguez-Payán AJ, Nava-Ruiz C.
    Brain Res; 2004 Mar 05; 999(2):212-5. PubMed ID: 14759500
    [Abstract] [Full Text] [Related]

  • 8. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.
    Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC.
    Exp Neurol; 2008 Jul 05; 212(1):53-62. PubMed ID: 18462720
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
    Allahtavakoli M, Shabanzadeh A, Roohbakhsh A, Pourshanazari A.
    Basic Clin Pharmacol Toxicol; 2007 Nov 05; 101(5):309-14. PubMed ID: 17910613
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator.
    Lapchak PA.
    Brain Res; 2010 Jan 14; 1309():136-45. PubMed ID: 19891959
    [Abstract] [Full Text] [Related]

  • 11. Oxyresveratrol (trans-2,3',4,5'-tetrahydroxystilbene) is neuroprotective and inhibits the apoptotic cell death in transient cerebral ischemia.
    Andrabi SA, Spina MG, Lorenz P, Ebmeyer U, Wolf G, Horn TF.
    Brain Res; 2004 Aug 13; 1017(1-2):98-107. PubMed ID: 15261105
    [Abstract] [Full Text] [Related]

  • 12. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats.
    Thiyagarajan M, Kaul CL, Sharma SS.
    Br J Pharmacol; 2004 Jul 13; 142(5):899-911. PubMed ID: 15197101
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke.
    Alonso de Leciñana M, Gutiérrez M, Roda JM, Carceller F, Díez-Tejedor E.
    J Neurol Sci; 2006 Sep 25; 247(2):121-9. PubMed ID: 16797595
    [Abstract] [Full Text] [Related]

  • 15. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.
    Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE.
    Neuroscience; 2005 Sep 25; 130(3):685-96. PubMed ID: 15590152
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats.
    Wang CX, Ding X, Noor R, Pegg C, He C, Shuaib A.
    J Cereb Blood Flow Metab; 2009 Oct 25; 29(10):1683-94. PubMed ID: 19553906
    [Abstract] [Full Text] [Related]

  • 20. Infarct reduction in rats following intraventricular administration of either tissue plasminogen activator (tPA) or its non-protease mutant S478A-tPA.
    Yi JS, Kim YH, Koh JY.
    Exp Neurol; 2004 Oct 25; 189(2):354-60. PubMed ID: 15380485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.